Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.06. | H.C. Wainwright nimmt Berichterstattung über ARTIVA-Aktie mit Kaufempfehlung auf | 2 | Investing.com Deutsch | ||
ARTIVA BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
11.06. | H.C. Wainwright assumes coverage on ARTIVA stock with buy rating | 3 | Investing.com | ||
13.05. | Artiva reports promising AlloNK therapy results in B-NHL study | 2 | Investing.com | ||
13.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT ... | 50 | GlobeNewswire (Europe) | 64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL... ► Artikel lesen | |
08.05. | Artiva Biotherapeutics GAAP EPS of -$0.83 | 2 | Seeking Alpha | ||
08.05. | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
08.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights | 100 | GlobeNewswire (Europe) | IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis ... ► Artikel lesen | |
08.05. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
28.04. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting | 2 | GlobeNewswire (USA) | ||
08.04. | Artiva Biotherapeutics names new Chief Medical Officer | 2 | Investing.com | ||
08.04. | Artiva Biotherapeutics ernennt neuen Chief Medical Officer | 5 | Investing.com Deutsch | ||
08.04. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer | 621 | GlobeNewswire (Europe) | SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies... ► Artikel lesen | |
26.03. | Artiva Biotherapeutics stock rises following analyst optimism | 2 | Investing.com | ||
26.03. | Artiva Biotherapeutics-Aktie steigt nach Analysten-Optimismus | 2 | Investing.com Deutsch | ||
24.03. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights | 111 | GlobeNewswire (Europe) | Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented... ► Artikel lesen | |
24.03. | Artiva Biotherapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
24.03. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
29.01. | Artiva Biotherapeutics expands board with industry veteran | 3 | Investing.com | ||
29.01. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
AMGEN | 237,00 | +0,11 % | Amgen-Aktie mit Kursverlusten (237,1233 €) | An der US-amerikanischen Börse notiert die Aktie von Amgen derzeit etwas leichter. Der jüngste Kurs betrug 277,19 US-Dollar. An der Börse liegt die Aktie von Amgen zur Stunde im Minus. Das Wertpapier... ► Artikel lesen | |
NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
BIOGEN | 108,05 | +0,32 % | Biogen Inc.: New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA | New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
BIOCRYST PHARMACEUTICALS | 7,834 | -1,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million | -Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones-
-BioCryst plans to use proceeds to... ► Artikel lesen | |
TEMPUS AI | 56,44 | -0,67 % | Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? | ||
SAREPTA THERAPEUTICS | 14,575 | -0,21 % | Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny | ||
CARDIOL THERAPEUTICS | 1,304 | +8,49 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
EXELIXIS | 37,080 | -0,59 % | ROUNDUP/Aktien New York: Entspannt nach US-Militärschlag und positiven Daten | NEW YORK (dpa-AFX) - Angesichts der bislang überschaubaren ökonomischen Auswirkungen des US-Militärschlags gegen den Iran sind die Anleger an den US-Börsen am Montag recht gelassen geblieben. Zudem... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -0,67 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock | ||
VAXART | 0,433 | +2,90 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen |